Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial Article Swipe
Nicholas F. Brown
,
Catherine McBain
,
Lucy Brazil
,
Sharon Peoples
,
Sarah Jefferies
,
Fiona Harris
,
Anup Vinayan
,
Puneet Plaha
,
Claire Brooks
,
Samia Hussain
,
Susan Dutton
,
Jonathan Cook
,
Stasya Ng
,
Stéphanie Lévy
,
Timothy J. Coutts
,
Paul Mulholland
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/noajnl/vdaf032
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/noajnl/vdaf032
Background Glioblastoma confers a bleak prognosis, with median survival of less than a year. This trial evaluated whether addition of the CTLA-4 immune checkpoint inhibitor ipilimumab to standard therapy improves survival in patients with recently diagnosed glioblastoma. Methods Ipi-Glio was a stratified randomized, open-label, multicenter, academic phase II study. Patients with recently diagnosed de novo glioblastoma following completion of chemoradiotherapy were randomized 2:1 to ipilimumab + temozolomide (Arm A) vs temozolomide alone (Arm B), stratified to extent of surgery and MGMT promotor methylation. Primary endpoint was overall survival. Secondary endpoints included progression-free survival at 18 months, overall survival at 3 years, and toxicity (≥Grade 3). Results One hundred nineteen patients were randomized (79 to Arm A, 40 to Arm B). Patient characteristics (Arm A vs B): median age 57 vs 49 years; male sex 70 vs 65%, gross total resection 61 vs 60%, tumor MGMT promotor methylation 39 vs 40%. Median overall survival was 18 months (60% CI 16.0, 23.9) in Arm A vs 23.0 months (17.3, 26.4) in Arm B (adjusted HR 1.09, 60% CI 0.86,1.38, one-sided P = .62; logrank P = .75). Progression-Free Survival: 10.8 vs 12.5 months (Arm A vs B) (adjusted HR 1.34, 1.06–1.68, one-sided P = .86;logrank P = .42). Grade 3 or above adverse events: 53% Arm A vs 43% Arm B (P = .27). Conclusions No benefit was observed with the addition of ipilimumab to temozolomide in patients with recently diagnosed glioblastoma following chemoradiotherapy. This study does not support further investigation of this regimen in this setting. Trial Registration ISRCTN84434175 (www.isrctn.com/ISRCTN84434175)
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/noajnl/vdaf032
- https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdaf032/63355064/vdaf032.pdf
- OA Status
- gold
- References
- 43
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4410731605
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4410731605Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/noajnl/vdaf032Digital Object Identifier
- Title
-
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trialWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-01-01Full publication date if available
- Authors
-
Nicholas F. Brown, Catherine McBain, Lucy Brazil, Sharon Peoples, Sarah Jefferies, Fiona Harris, Anup Vinayan, Puneet Plaha, Claire Brooks, Samia Hussain, Susan Dutton, Jonathan Cook, Stasya Ng, Stéphanie Lévy, Timothy J. Coutts, Paul MulhollandList of authors in order
- Landing page
-
https://doi.org/10.1093/noajnl/vdaf032Publisher landing page
- PDF URL
-
https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdaf032/63355064/vdaf032.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdaf032/63355064/vdaf032.pdfDirect OA link when available
- Concepts
-
Temozolomide, Ipilimumab, Medicine, Clinical endpoint, Internal medicine, Progression-free survival, Chemoradiotherapy, Surgery, Phases of clinical research, Adverse effect, Oncology, Clinical trial, Radiation therapy, Chemotherapy, Cancer, ImmunotherapyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
43Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4410731605 |
|---|---|
| doi | https://doi.org/10.1093/noajnl/vdaf032 |
| ids.doi | https://doi.org/10.1093/noajnl/vdaf032 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40800123 |
| ids.openalex | https://openalex.org/W4410731605 |
| fwci | 0.0 |
| type | article |
| title | Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial |
| biblio.issue | 1 |
| biblio.volume | 7 |
| biblio.last_page | vdaf032 |
| biblio.first_page | vdaf032 |
| topics[0].id | https://openalex.org/T10129 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9997000098228455 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2716 |
| topics[0].subfield.display_name | Genetics |
| topics[0].display_name | Glioma Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T10158 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9987999796867371 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cancer Immunotherapy and Biomarkers |
| topics[2].id | https://openalex.org/T11600 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9962999820709229 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2740 |
| topics[2].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[2].display_name | Brain Metastases and Treatment |
| is_xpac | False |
| apc_list.value | 1622 |
| apc_list.currency | GBP |
| apc_list.value_usd | 1989 |
| apc_paid.value | 1622 |
| apc_paid.currency | GBP |
| apc_paid.value_usd | 1989 |
| concepts[0].id | https://openalex.org/C2777389519 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9388011693954468 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q425088 |
| concepts[0].display_name | Temozolomide |
| concepts[1].id | https://openalex.org/C2781433595 |
| concepts[1].level | 4 |
| concepts[1].score | 0.9331438541412354 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q2459042 |
| concepts[1].display_name | Ipilimumab |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.8956518173217773 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C203092338 |
| concepts[3].level | 3 |
| concepts[3].score | 0.7475666403770447 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1340863 |
| concepts[3].display_name | Clinical endpoint |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6276490688323975 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C2780739268 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5257585644721985 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2112244 |
| concepts[5].display_name | Progression-free survival |
| concepts[6].id | https://openalex.org/C2778424827 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5157546997070312 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q5090613 |
| concepts[6].display_name | Chemoradiotherapy |
| concepts[7].id | https://openalex.org/C141071460 |
| concepts[7].level | 1 |
| concepts[7].score | 0.47777068614959717 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[7].display_name | Surgery |
| concepts[8].id | https://openalex.org/C31760486 |
| concepts[8].level | 3 |
| concepts[8].score | 0.46285122632980347 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7180990 |
| concepts[8].display_name | Phases of clinical research |
| concepts[9].id | https://openalex.org/C197934379 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4348451495170593 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[9].display_name | Adverse effect |
| concepts[10].id | https://openalex.org/C143998085 |
| concepts[10].level | 1 |
| concepts[10].score | 0.41802603006362915 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[10].display_name | Oncology |
| concepts[11].id | https://openalex.org/C535046627 |
| concepts[11].level | 2 |
| concepts[11].score | 0.38027316331863403 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[11].display_name | Clinical trial |
| concepts[12].id | https://openalex.org/C509974204 |
| concepts[12].level | 2 |
| concepts[12].score | 0.32747527956962585 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q180507 |
| concepts[12].display_name | Radiation therapy |
| concepts[13].id | https://openalex.org/C2776694085 |
| concepts[13].level | 2 |
| concepts[13].score | 0.2651096284389496 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[13].display_name | Chemotherapy |
| concepts[14].id | https://openalex.org/C121608353 |
| concepts[14].level | 2 |
| concepts[14].score | 0.204135924577713 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[14].display_name | Cancer |
| concepts[15].id | https://openalex.org/C2777701055 |
| concepts[15].level | 3 |
| concepts[15].score | 0.14268869161605835 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[15].display_name | Immunotherapy |
| keywords[0].id | https://openalex.org/keywords/temozolomide |
| keywords[0].score | 0.9388011693954468 |
| keywords[0].display_name | Temozolomide |
| keywords[1].id | https://openalex.org/keywords/ipilimumab |
| keywords[1].score | 0.9331438541412354 |
| keywords[1].display_name | Ipilimumab |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.8956518173217773 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/clinical-endpoint |
| keywords[3].score | 0.7475666403770447 |
| keywords[3].display_name | Clinical endpoint |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.6276490688323975 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/progression-free-survival |
| keywords[5].score | 0.5257585644721985 |
| keywords[5].display_name | Progression-free survival |
| keywords[6].id | https://openalex.org/keywords/chemoradiotherapy |
| keywords[6].score | 0.5157546997070312 |
| keywords[6].display_name | Chemoradiotherapy |
| keywords[7].id | https://openalex.org/keywords/surgery |
| keywords[7].score | 0.47777068614959717 |
| keywords[7].display_name | Surgery |
| keywords[8].id | https://openalex.org/keywords/phases-of-clinical-research |
| keywords[8].score | 0.46285122632980347 |
| keywords[8].display_name | Phases of clinical research |
| keywords[9].id | https://openalex.org/keywords/adverse-effect |
| keywords[9].score | 0.4348451495170593 |
| keywords[9].display_name | Adverse effect |
| keywords[10].id | https://openalex.org/keywords/oncology |
| keywords[10].score | 0.41802603006362915 |
| keywords[10].display_name | Oncology |
| keywords[11].id | https://openalex.org/keywords/clinical-trial |
| keywords[11].score | 0.38027316331863403 |
| keywords[11].display_name | Clinical trial |
| keywords[12].id | https://openalex.org/keywords/radiation-therapy |
| keywords[12].score | 0.32747527956962585 |
| keywords[12].display_name | Radiation therapy |
| keywords[13].id | https://openalex.org/keywords/chemotherapy |
| keywords[13].score | 0.2651096284389496 |
| keywords[13].display_name | Chemotherapy |
| keywords[14].id | https://openalex.org/keywords/cancer |
| keywords[14].score | 0.204135924577713 |
| keywords[14].display_name | Cancer |
| keywords[15].id | https://openalex.org/keywords/immunotherapy |
| keywords[15].score | 0.14268869161605835 |
| keywords[15].display_name | Immunotherapy |
| language | en |
| locations[0].id | doi:10.1093/noajnl/vdaf032 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210237914 |
| locations[0].source.issn | 2632-2498 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2632-2498 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Neuro-Oncology Advances |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdaf032/63355064/vdaf032.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Neuro-Oncology Advances |
| locations[0].landing_page_url | https://doi.org/10.1093/noajnl/vdaf032 |
| locations[1].id | pmid:40800123 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Neuro-oncology advances |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40800123 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:12342986 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Neurooncol Adv |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12342986 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5061818587 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-9036-884X |
| authorships[0].author.display_name | Nicholas F. Brown |
| authorships[0].countries | GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2801259928, https://openalex.org/I45129253 |
| authorships[0].affiliations[0].raw_affiliation_string | University College London Hospitals, 250 Euston Road, London , NW1 2PQ. United Kingdom |
| authorships[0].institutions[0].id | https://openalex.org/I2801259928 |
| authorships[0].institutions[0].ror | https://ror.org/019my5047 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I225661044, https://openalex.org/I2801259928 |
| authorships[0].institutions[0].country_code | GB |
| authorships[0].institutions[0].display_name | Royal London Hospital |
| authorships[0].institutions[1].id | https://openalex.org/I45129253 |
| authorships[0].institutions[1].ror | https://ror.org/02jx3x895 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I124357947, https://openalex.org/I45129253 |
| authorships[0].institutions[1].country_code | GB |
| authorships[0].institutions[1].display_name | University College London |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Nicholas F Brown |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | University College London Hospitals, 250 Euston Road, London , NW1 2PQ. United Kingdom |
| authorships[1].author.id | https://openalex.org/A5015933098 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9281-3767 |
| authorships[1].author.display_name | Catherine McBain |
| authorships[1].affiliations[0].raw_affiliation_string | The Christine NHS Foundation Trust, Wilmslow Road, Manchester , M20 4BX. United Kingdom |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Catherine McBain |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | The Christine NHS Foundation Trust, Wilmslow Road, Manchester , M20 4BX. United Kingdom |
| authorships[2].author.id | https://openalex.org/A5113052338 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Lucy Brazil |
| authorships[2].countries | GB |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I200166805 |
| authorships[2].affiliations[0].raw_affiliation_string | Guys Cancer, Guys and St Thomas’ NHS Foundation Trust, Great Maze Pond , London SE1 3SS. United Kingdom |
| authorships[2].institutions[0].id | https://openalex.org/I200166805 |
| authorships[2].institutions[0].ror | https://ror.org/00j161312 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I200166805 |
| authorships[2].institutions[0].country_code | GB |
| authorships[2].institutions[0].display_name | Guy's and St Thomas' NHS Foundation Trust |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Lucy Brazil |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Guys Cancer, Guys and St Thomas’ NHS Foundation Trust, Great Maze Pond , London SE1 3SS. United Kingdom |
| authorships[3].author.id | https://openalex.org/A5110464945 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Sharon Peoples |
| authorships[3].countries | GB |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2800150677, https://openalex.org/I2802581871 |
| authorships[3].affiliations[0].raw_affiliation_string | Edinburgh Centre for Neuro-Oncology , Western General Hospital Edinburgh Cancer Centre, Edinburgh EH4 2LF. United Kingdom |
| authorships[3].institutions[0].id | https://openalex.org/I2802581871 |
| authorships[3].institutions[0].ror | https://ror.org/05a7t9b67 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I2801316944, https://openalex.org/I2802581871, https://openalex.org/I98677209 |
| authorships[3].institutions[0].country_code | GB |
| authorships[3].institutions[0].display_name | Edinburgh Cancer Research |
| authorships[3].institutions[1].id | https://openalex.org/I2800150677 |
| authorships[3].institutions[1].ror | https://ror.org/009kr6r15 |
| authorships[3].institutions[1].type | healthcare |
| authorships[3].institutions[1].lineage | https://openalex.org/I1324252669, https://openalex.org/I2800150677 |
| authorships[3].institutions[1].country_code | GB |
| authorships[3].institutions[1].display_name | Western General Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Sharon Peoples |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Edinburgh Centre for Neuro-Oncology , Western General Hospital Edinburgh Cancer Centre, Edinburgh EH4 2LF. United Kingdom |
| authorships[4].author.id | https://openalex.org/A5015927579 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-7660-4466 |
| authorships[4].author.display_name | Sarah Jefferies |
| authorships[4].countries | GB |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2802466933 |
| authorships[4].affiliations[0].raw_affiliation_string | Cambridge University Hospitals NHS Foundation Trust, Hills Road , Cambridge, CB2 0QQ. United Kingdom |
| authorships[4].institutions[0].id | https://openalex.org/I2802466933 |
| authorships[4].institutions[0].ror | https://ror.org/04v54gj93 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I2802466933 |
| authorships[4].institutions[0].country_code | GB |
| authorships[4].institutions[0].display_name | Cambridge University Hospitals NHS Foundation Trust |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sarah Jefferies |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Cambridge University Hospitals NHS Foundation Trust, Hills Road , Cambridge, CB2 0QQ. United Kingdom |
| authorships[5].author.id | https://openalex.org/A5050022885 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-8919-067X |
| authorships[5].author.display_name | Fiona Harris |
| authorships[5].countries | GB |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I2802466933 |
| authorships[5].affiliations[0].raw_affiliation_string | Cambridge University Hospitals NHS Foundation Trust, Hills Road , Cambridge, CB2 0QQ. United Kingdom |
| authorships[5].institutions[0].id | https://openalex.org/I2802466933 |
| authorships[5].institutions[0].ror | https://ror.org/04v54gj93 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I2802466933 |
| authorships[5].institutions[0].country_code | GB |
| authorships[5].institutions[0].display_name | Cambridge University Hospitals NHS Foundation Trust |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Fiona Harris |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Cambridge University Hospitals NHS Foundation Trust, Hills Road , Cambridge, CB2 0QQ. United Kingdom |
| authorships[6].author.id | https://openalex.org/A5083313815 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Anup Vinayan |
| authorships[6].countries | GB |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210108939 |
| authorships[6].affiliations[0].raw_affiliation_string | Mount Vernon Cancer Centre, Rickmansworth Road , Northwood, HA6 2RN. United Kingdom |
| authorships[6].institutions[0].id | https://openalex.org/I4210108939 |
| authorships[6].institutions[0].ror | https://ror.org/01wwv4x50 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210108939, https://openalex.org/I4210122718 |
| authorships[6].institutions[0].country_code | GB |
| authorships[6].institutions[0].display_name | Mount Vernon Cancer Centre |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Anup Vinayan |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Mount Vernon Cancer Centre, Rickmansworth Road , Northwood, HA6 2RN. United Kingdom |
| authorships[7].author.id | https://openalex.org/A5020317135 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-3103-6359 |
| authorships[7].author.display_name | Puneet Plaha |
| authorships[7].countries | GB |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210147381 |
| authorships[7].affiliations[0].raw_affiliation_string | Oxford University Hospitals, Headley Way , Headington, Oxford OX3 9DU. United Kingdom |
| authorships[7].institutions[0].id | https://openalex.org/I4210147381 |
| authorships[7].institutions[0].ror | https://ror.org/03h2bh287 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210147381 |
| authorships[7].institutions[0].country_code | GB |
| authorships[7].institutions[0].display_name | Oxford University Hospitals NHS Trust |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Puneet Plaha |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Oxford University Hospitals, Headley Way , Headington, Oxford OX3 9DU. United Kingdom |
| authorships[8].author.id | https://openalex.org/A5090581597 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-3410-8971 |
| authorships[8].author.display_name | Claire Brooks |
| authorships[8].countries | GB |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I40120149 |
| authorships[8].affiliations[0].raw_affiliation_string | Oncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford , Old Road Campus Research Building, Oxford, OX3 7DQ. United Kingdom |
| authorships[8].institutions[0].id | https://openalex.org/I40120149 |
| authorships[8].institutions[0].ror | https://ror.org/052gg0110 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I40120149 |
| authorships[8].institutions[0].country_code | GB |
| authorships[8].institutions[0].display_name | University of Oxford |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Claire Brooks |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Oncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford , Old Road Campus Research Building, Oxford, OX3 7DQ. United Kingdom |
| authorships[9].author.id | https://openalex.org/A5060069942 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Samia Hussain |
| authorships[9].countries | GB |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I40120149 |
| authorships[9].affiliations[0].raw_affiliation_string | Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine (CSM), University of Oxford , Botnar Research Centre, Windmill Road, Oxford, OX3 7LD. United Kingdom |
| authorships[9].institutions[0].id | https://openalex.org/I40120149 |
| authorships[9].institutions[0].ror | https://ror.org/052gg0110 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I40120149 |
| authorships[9].institutions[0].country_code | GB |
| authorships[9].institutions[0].display_name | University of Oxford |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Samia Hussain |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine (CSM), University of Oxford , Botnar Research Centre, Windmill Road, Oxford, OX3 7LD. United Kingdom |
| authorships[10].author.id | https://openalex.org/A5075349431 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-4573-5257 |
| authorships[10].author.display_name | Susan Dutton |
| authorships[10].countries | GB |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I40120149 |
| authorships[10].affiliations[0].raw_affiliation_string | Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine (CSM), University of Oxford , Botnar Research Centre, Windmill Road, Oxford, OX3 7LD. United Kingdom |
| authorships[10].institutions[0].id | https://openalex.org/I40120149 |
| authorships[10].institutions[0].ror | https://ror.org/052gg0110 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I40120149 |
| authorships[10].institutions[0].country_code | GB |
| authorships[10].institutions[0].display_name | University of Oxford |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Susan J Dutton |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine (CSM), University of Oxford , Botnar Research Centre, Windmill Road, Oxford, OX3 7LD. United Kingdom |
| authorships[11].author.id | https://openalex.org/A5018731744 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-4156-6989 |
| authorships[11].author.display_name | Jonathan Cook |
| authorships[11].countries | GB |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I40120149 |
| authorships[11].affiliations[0].raw_affiliation_string | Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine (CSM), University of Oxford , Botnar Research Centre, Windmill Road, Oxford, OX3 7LD. United Kingdom |
| authorships[11].institutions[0].id | https://openalex.org/I40120149 |
| authorships[11].institutions[0].ror | https://ror.org/052gg0110 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I40120149 |
| authorships[11].institutions[0].country_code | GB |
| authorships[11].institutions[0].display_name | University of Oxford |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Jonathan Cook |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine (CSM), University of Oxford , Botnar Research Centre, Windmill Road, Oxford, OX3 7LD. United Kingdom |
| authorships[12].author.id | https://openalex.org/A5112429531 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Stasya Ng |
| authorships[12].countries | GB |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I40120149 |
| authorships[12].affiliations[0].raw_affiliation_string | Oncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford , Old Road Campus Research Building, Oxford, OX3 7DQ. United Kingdom |
| authorships[12].institutions[0].id | https://openalex.org/I40120149 |
| authorships[12].institutions[0].ror | https://ror.org/052gg0110 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I40120149 |
| authorships[12].institutions[0].country_code | GB |
| authorships[12].institutions[0].display_name | University of Oxford |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Stasya M Ng |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Oncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford , Old Road Campus Research Building, Oxford, OX3 7DQ. United Kingdom |
| authorships[13].author.id | https://openalex.org/A5083650031 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-2828-2014 |
| authorships[13].author.display_name | Stéphanie Lévy |
| authorships[13].countries | GB |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I40120149 |
| authorships[13].affiliations[0].raw_affiliation_string | Oncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford , Old Road Campus Research Building, Oxford, OX3 7DQ. United Kingdom |
| authorships[13].institutions[0].id | https://openalex.org/I40120149 |
| authorships[13].institutions[0].ror | https://ror.org/052gg0110 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I40120149 |
| authorships[13].institutions[0].country_code | GB |
| authorships[13].institutions[0].display_name | University of Oxford |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Stephanie Levy |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Oncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford , Old Road Campus Research Building, Oxford, OX3 7DQ. United Kingdom |
| authorships[14].author.id | https://openalex.org/A5110882726 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Timothy J. Coutts |
| authorships[14].countries | GB |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I40120149 |
| authorships[14].affiliations[0].raw_affiliation_string | Oncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford , Old Road Campus Research Building, Oxford, OX3 7DQ. United Kingdom |
| authorships[14].institutions[0].id | https://openalex.org/I40120149 |
| authorships[14].institutions[0].ror | https://ror.org/052gg0110 |
| authorships[14].institutions[0].type | education |
| authorships[14].institutions[0].lineage | https://openalex.org/I40120149 |
| authorships[14].institutions[0].country_code | GB |
| authorships[14].institutions[0].display_name | University of Oxford |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Timothy Coutts |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Oncology Clinical Trials Office (OCTO), Department of Oncology, The University of Oxford , Old Road Campus Research Building, Oxford, OX3 7DQ. United Kingdom |
| authorships[15].author.id | https://openalex.org/A5050246084 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-7926-824X |
| authorships[15].author.display_name | Paul Mulholland |
| authorships[15].countries | GB |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I2801259928, https://openalex.org/I45129253 |
| authorships[15].affiliations[0].raw_affiliation_string | University College London Hospitals, 250 Euston Road, London , NW1 2PQ. United Kingdom |
| authorships[15].affiliations[1].institution_ids | https://openalex.org/I4210147892, https://openalex.org/I45129253 |
| authorships[15].affiliations[1].raw_affiliation_string | UCL Cancer Institute, 72 Huntley St , London WC1E 6AG. United Kingdom |
| authorships[15].institutions[0].id | https://openalex.org/I4210147892 |
| authorships[15].institutions[0].ror | https://ror.org/04nm2mq63 |
| authorships[15].institutions[0].type | facility |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210147892 |
| authorships[15].institutions[0].country_code | GB |
| authorships[15].institutions[0].display_name | CRUK Lung Cancer Centre of Excellence |
| authorships[15].institutions[1].id | https://openalex.org/I2801259928 |
| authorships[15].institutions[1].ror | https://ror.org/019my5047 |
| authorships[15].institutions[1].type | healthcare |
| authorships[15].institutions[1].lineage | https://openalex.org/I225661044, https://openalex.org/I2801259928 |
| authorships[15].institutions[1].country_code | GB |
| authorships[15].institutions[1].display_name | Royal London Hospital |
| authorships[15].institutions[2].id | https://openalex.org/I45129253 |
| authorships[15].institutions[2].ror | https://ror.org/02jx3x895 |
| authorships[15].institutions[2].type | education |
| authorships[15].institutions[2].lineage | https://openalex.org/I124357947, https://openalex.org/I45129253 |
| authorships[15].institutions[2].country_code | GB |
| authorships[15].institutions[2].display_name | University College London |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | Paul Mulholland |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | UCL Cancer Institute, 72 Huntley St , London WC1E 6AG. United Kingdom, University College London Hospitals, 250 Euston Road, London , NW1 2PQ. United Kingdom |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdaf032/63355064/vdaf032.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-05-26T00:00:00 |
| display_name | Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10129 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9997000098228455 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2716 |
| primary_topic.subfield.display_name | Genetics |
| primary_topic.display_name | Glioma Diagnosis and Treatment |
| related_works | https://openalex.org/W2118311655, https://openalex.org/W2042969729, https://openalex.org/W2302413146, https://openalex.org/W4404650946, https://openalex.org/W2770013878, https://openalex.org/W2078219238, https://openalex.org/W1986632087, https://openalex.org/W2121585125, https://openalex.org/W2123133319, https://openalex.org/W2066351996 |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1093/noajnl/vdaf032 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210237914 |
| best_oa_location.source.issn | 2632-2498 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2632-2498 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Neuro-Oncology Advances |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdaf032/63355064/vdaf032.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Neuro-Oncology Advances |
| best_oa_location.landing_page_url | https://doi.org/10.1093/noajnl/vdaf032 |
| primary_location.id | doi:10.1093/noajnl/vdaf032 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210237914 |
| primary_location.source.issn | 2632-2498 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2632-2498 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Neuro-Oncology Advances |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdaf032/63355064/vdaf032.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Neuro-Oncology Advances |
| primary_location.landing_page_url | https://doi.org/10.1093/noajnl/vdaf032 |
| publication_date | 2025-01-01 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3174246647, https://openalex.org/W4283702940, https://openalex.org/W2896657197, https://openalex.org/W1995121009, https://openalex.org/W4301595791, https://openalex.org/W2156330848, https://openalex.org/W2124736921, https://openalex.org/W2020812892, https://openalex.org/W2320482285, https://openalex.org/W2158681922, https://openalex.org/W2205491921, https://openalex.org/W4223897107, https://openalex.org/W2096287682, https://openalex.org/W2436534309, https://openalex.org/W2089640963, https://openalex.org/W1562353925, https://openalex.org/W2141570482, https://openalex.org/W2105100844, https://openalex.org/W2035021866, https://openalex.org/W2899024441, https://openalex.org/W1983955583, https://openalex.org/W2046739604, https://openalex.org/W2190672185, https://openalex.org/W2097049582, https://openalex.org/W2103220202, https://openalex.org/W1979651049, https://openalex.org/W3011587695, https://openalex.org/W3217143832, https://openalex.org/W4388588970, https://openalex.org/W3026551532, https://openalex.org/W2996809166, https://openalex.org/W2913623258, https://openalex.org/W2885696745, https://openalex.org/W2911871569, https://openalex.org/W4316661381, https://openalex.org/W6787313408, https://openalex.org/W4389545728, https://openalex.org/W2123808042, https://openalex.org/W2160959204, https://openalex.org/W2101922439, https://openalex.org/W2163910135, https://openalex.org/W1994497191, https://openalex.org/W6726068737 |
| referenced_works_count | 43 |
| abstract_inverted_index.+ | 66 |
| abstract_inverted_index.3 | 100, 208 |
| abstract_inverted_index.= | 180, 184, 202, 205, 221 |
| abstract_inverted_index.A | 124, 163, 193, 215 |
| abstract_inverted_index.B | 171, 219 |
| abstract_inverted_index.P | 179, 183, 201, 204 |
| abstract_inverted_index.a | 4, 13, 41 |
| abstract_inverted_index.(P | 220 |
| abstract_inverted_index.18 | 95, 155 |
| abstract_inverted_index.39 | 148 |
| abstract_inverted_index.40 | 117 |
| abstract_inverted_index.49 | 131 |
| abstract_inverted_index.57 | 129 |
| abstract_inverted_index.61 | 141 |
| abstract_inverted_index.70 | 135 |
| abstract_inverted_index.A) | 69 |
| abstract_inverted_index.A, | 116 |
| abstract_inverted_index.B) | 195 |
| abstract_inverted_index.CI | 158, 176 |
| abstract_inverted_index.HR | 173, 197 |
| abstract_inverted_index.II | 48 |
| abstract_inverted_index.No | 224 |
| abstract_inverted_index.at | 94, 99 |
| abstract_inverted_index.de | 54 |
| abstract_inverted_index.in | 32, 161, 169, 235, 253 |
| abstract_inverted_index.of | 10, 20, 59, 78, 231, 250 |
| abstract_inverted_index.or | 209 |
| abstract_inverted_index.to | 27, 64, 76, 114, 118, 233 |
| abstract_inverted_index.vs | 70, 125, 130, 136, 142, 149, 164, 189, 194, 216 |
| abstract_inverted_index.(79 | 113 |
| abstract_inverted_index.2:1 | 63 |
| abstract_inverted_index.3). | 105 |
| abstract_inverted_index.43% | 217 |
| abstract_inverted_index.53% | 213 |
| abstract_inverted_index.60% | 175 |
| abstract_inverted_index.Arm | 115, 119, 162, 170, 214, 218 |
| abstract_inverted_index.B), | 74 |
| abstract_inverted_index.B). | 120 |
| abstract_inverted_index.B): | 126 |
| abstract_inverted_index.One | 107 |
| abstract_inverted_index.age | 128 |
| abstract_inverted_index.and | 80, 102 |
| abstract_inverted_index.not | 246 |
| abstract_inverted_index.sex | 134 |
| abstract_inverted_index.the | 21, 229 |
| abstract_inverted_index.was | 40, 86, 154, 226 |
| abstract_inverted_index.(60% | 157 |
| abstract_inverted_index.(Arm | 68, 73, 123, 192 |
| abstract_inverted_index..62; | 181 |
| abstract_inverted_index.10.8 | 188 |
| abstract_inverted_index.12.5 | 190 |
| abstract_inverted_index.23.0 | 165 |
| abstract_inverted_index.40%. | 150 |
| abstract_inverted_index.60%, | 143 |
| abstract_inverted_index.65%, | 137 |
| abstract_inverted_index.MGMT | 81, 145 |
| abstract_inverted_index.This | 15, 243 |
| abstract_inverted_index.does | 245 |
| abstract_inverted_index.less | 11 |
| abstract_inverted_index.male | 133 |
| abstract_inverted_index.novo | 55 |
| abstract_inverted_index.than | 12 |
| abstract_inverted_index.this | 251, 254 |
| abstract_inverted_index.were | 61, 111 |
| abstract_inverted_index.with | 7, 34, 51, 228, 237 |
| abstract_inverted_index..27). | 222 |
| abstract_inverted_index..42). | 206 |
| abstract_inverted_index..75). | 185 |
| abstract_inverted_index.1.09, | 174 |
| abstract_inverted_index.1.34, | 198 |
| abstract_inverted_index.16.0, | 159 |
| abstract_inverted_index.23.9) | 160 |
| abstract_inverted_index.26.4) | 168 |
| abstract_inverted_index.Grade | 207 |
| abstract_inverted_index.Trial | 256 |
| abstract_inverted_index.above | 210 |
| abstract_inverted_index.alone | 72 |
| abstract_inverted_index.bleak | 5 |
| abstract_inverted_index.gross | 138 |
| abstract_inverted_index.phase | 47 |
| abstract_inverted_index.study | 244 |
| abstract_inverted_index.total | 139 |
| abstract_inverted_index.trial | 16 |
| abstract_inverted_index.tumor | 144 |
| abstract_inverted_index.year. | 14 |
| abstract_inverted_index.(17.3, | 167 |
| abstract_inverted_index.CTLA-4 | 22 |
| abstract_inverted_index.Median | 151 |
| abstract_inverted_index.extent | 77 |
| abstract_inverted_index.immune | 23 |
| abstract_inverted_index.median | 8, 127 |
| abstract_inverted_index.months | 156, 166, 191 |
| abstract_inverted_index.study. | 49 |
| abstract_inverted_index.years, | 101 |
| abstract_inverted_index.years; | 132 |
| abstract_inverted_index.Methods | 38 |
| abstract_inverted_index.Patient | 121 |
| abstract_inverted_index.Primary | 84 |
| abstract_inverted_index.Results | 106 |
| abstract_inverted_index.adverse | 211 |
| abstract_inverted_index.benefit | 225 |
| abstract_inverted_index.confers | 3 |
| abstract_inverted_index.events: | 212 |
| abstract_inverted_index.further | 248 |
| abstract_inverted_index.hundred | 108 |
| abstract_inverted_index.logrank | 182 |
| abstract_inverted_index.months, | 96 |
| abstract_inverted_index.overall | 87, 97, 152 |
| abstract_inverted_index.regimen | 252 |
| abstract_inverted_index.support | 247 |
| abstract_inverted_index.surgery | 79 |
| abstract_inverted_index.therapy | 29 |
| abstract_inverted_index.whether | 18 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Ipi-Glio | 39 |
| abstract_inverted_index.Patients | 50 |
| abstract_inverted_index.academic | 46 |
| abstract_inverted_index.addition | 19, 230 |
| abstract_inverted_index.endpoint | 85 |
| abstract_inverted_index.improves | 30 |
| abstract_inverted_index.included | 91 |
| abstract_inverted_index.nineteen | 109 |
| abstract_inverted_index.observed | 227 |
| abstract_inverted_index.patients | 33, 110, 236 |
| abstract_inverted_index.promotor | 82, 146 |
| abstract_inverted_index.recently | 35, 52, 238 |
| abstract_inverted_index.setting. | 255 |
| abstract_inverted_index.standard | 28 |
| abstract_inverted_index.survival | 9, 31, 93, 98, 153 |
| abstract_inverted_index.toxicity | 103 |
| abstract_inverted_index.(adjusted | 172, 196 |
| abstract_inverted_index.(≥Grade | 104 |
| abstract_inverted_index.Secondary | 89 |
| abstract_inverted_index.Survival: | 187 |
| abstract_inverted_index.diagnosed | 36, 53, 239 |
| abstract_inverted_index.endpoints | 90 |
| abstract_inverted_index.evaluated | 17 |
| abstract_inverted_index.following | 57, 241 |
| abstract_inverted_index.inhibitor | 25 |
| abstract_inverted_index.one-sided | 178, 200 |
| abstract_inverted_index.resection | 140 |
| abstract_inverted_index.survival. | 88 |
| abstract_inverted_index.0.86,1.38, | 177 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.checkpoint | 24 |
| abstract_inverted_index.completion | 58 |
| abstract_inverted_index.ipilimumab | 26, 65, 232 |
| abstract_inverted_index.prognosis, | 6 |
| abstract_inverted_index.randomized | 62, 112 |
| abstract_inverted_index.stratified | 42, 75 |
| abstract_inverted_index..86;logrank | 203 |
| abstract_inverted_index.Conclusions | 223 |
| abstract_inverted_index.methylation | 147 |
| abstract_inverted_index.open-label, | 44 |
| abstract_inverted_index.randomized, | 43 |
| abstract_inverted_index.1.06–1.68, | 199 |
| abstract_inverted_index.Glioblastoma | 2 |
| abstract_inverted_index.Registration | 257 |
| abstract_inverted_index.glioblastoma | 56, 240 |
| abstract_inverted_index.methylation. | 83 |
| abstract_inverted_index.multicenter, | 45 |
| abstract_inverted_index.temozolomide | 67, 71, 234 |
| abstract_inverted_index.glioblastoma. | 37 |
| abstract_inverted_index.investigation | 249 |
| abstract_inverted_index.ISRCTN84434175 | 258 |
| abstract_inverted_index.characteristics | 122 |
| abstract_inverted_index.Progression-Free | 186 |
| abstract_inverted_index.progression-free | 92 |
| abstract_inverted_index.chemoradiotherapy | 60 |
| abstract_inverted_index.chemoradiotherapy. | 242 |
| abstract_inverted_index.(www.isrctn.com/ISRCTN84434175) | 259 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 16 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.2626973 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |